Atara Biotherapeutics

Yahoo Finance • 6 hours ago

Mizuho lowers Atara Biotherapeutics stock price target on delayed tab-cel launch

Investing.com - Mizuho has lowered its price target on Atara Biotherapeutics (NASDAQ:ATRA) to $16.00 from $18.00 while maintaining an Outperform rating on the stock. The company, currently trading at $12.29 with a market cap of $83.52 mill... Full story

Yahoo Finance • 25 days ago

Atara gets FDA priority review for Tabelecleucel application

[group of virus] Jonathan Kitchen * Atara Biotherapeutics (NASDAQ:ATRA [https://seekingalpha.com/symbol/ATRA]) shares up after the company said that its marketing application for Tabelecleucel received priority review from the U.S. FDA.... Full story

Yahoo Finance • 27 days ago

Atara gains after insider purchase

[$100 Growth Rolling Banknote, Green Arrow, Object + Shadow Clipping Path] * Shares of Atara Biotherapeutics (NASDAQ:ATRA [https://seekingalpha.com/symbol/ATRA]) spiked for the second straight session on Tuesday following an insider pur... Full story

Yahoo Finance • 6 months ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that i... Full story

Yahoo Finance • 2 years ago

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

ATA3431 Preclinical Data Demonstrates Superior In Vivo Anti-tumor Activity, Survival, and Functional Persistence Compared to Autologous CAR-T Benchmark No Observed Treatment-Related Toxicities or Alloreactivity Data Supports Advancement... Full story

Yahoo Finance • 2 years ago

Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference

THOUSAND OAKS, Calif., November 22, 2023--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative the... Full story

Yahoo Finance • 2 years ago

Atara Biotherapeutics To Participate at the Stifel Healthcare Conference

THOUSAND OAKS, Calif., November 10, 2023--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative the... Full story

Yahoo Finance • 2 years ago

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript November 4, 2023 Operator: Good morning, and thank you for standing by. Welcome to Atara Biotherapeutics’ Third Quarter 2023 Financial Results Conference Call. [Op... Full story

Yahoo Finance • 2 years ago

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

THOUSAND OAKS, Calif., July 07, 2023--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapi... Full story

Yahoo Finance • 3 years ago

Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

THOUSAND OAKS, Calif., January 04, 2023--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative ther... Full story

Yahoo Finance • 3 years ago

Atara Biotherapeutics Announces Changes to Its Board of Directors

THOUSAND OAKS, Calif., December 19, 2022--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Carol Gallagher will assume the role of Chair of the Board of Directors, replacing Ron Renaud, who is stepping down... Full story

Yahoo Finance • 3 years ago

Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

Sustained Improvement Observed in ATA188 Treated Patients Achieving Confirmed Disability Improvement (CDI) in Open Label Extension (OLE) with up to 46 Months Follow up Patients Treated with ATA188 that Achieved CDI Demonstrate Significant... Full story

Yahoo Finance • 3 years ago

Bragar Eagel & Squire, P.C. Is Investigating Fulgent, Generac, Atara, and Clariant and Encourages Investors to Contact the Firm

NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (NASDAQ: FLGT), Generac Holdings, Inc. (NYSE:... Full story

Yahoo Finance • 3 years ago

Bragar Eagel & Squire, P.C. Is Investigating TuSimple, Atara, Mercury, and the WWE and Encourages Investors to Contact the Firm

NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against TuSimple Holdings, Inc. (NASDAQ: TSP), Atara Biotherapeutics, Inc. (N... Full story

Yahoo Finance • 3 years ago

Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022

Live Conference Call and Webcast at 4:30 p.m. EDT SOUTH SAN FRANCISCO, Calif., April 28, 2022--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr vir... Full story